Broker BMO lifted its price target on drugmaker Structure Therapeutics (NASDAQ: GPCR). The stock has a mean recommendation rating of 1.4 on a scale of one to five. The consensus mean price target is US$81.80.
Broker J.P. Morgan raised its rating and price target on REIT firm DigitalBridge (NYSE: DRBG). The stock has a mean recommendation rating of 1.9 on a scale of one to five. The consensus mean price target is US$21.61.
Broker BTIG raised its price target on Hudson Pacific as the resolution of the ongoing actors’ strike is expected to draw in demand recovery for HPP’s studio business. After the increase, HPP’s share price surged 2.1% on September 26, 2023.
Brokers raise their price targets on FedEx as the company gains consumers from rival firms’ recent business slowdown. After this update, FDX’s share price surged 2.63% to US$267.97 on September 25, 2023.
Brokers BTIG, Needham and Stifel Nicolaus and Company raised their price targets on BSX. Boston Scientific expects sales in Q3 2023 to be 8.5% to 10.5% higher than that in Q3 2022.
Broker Mizuho upgraded food delivery firm DoorDash (NYSE: DASH) to ‘buy’ and raised its price target on DASH to US$105. The upgrade led to the company’s stock price rising by 2% on September 18, 2023.
Broker Wells Fargo upgraded pharmaceutical firm Apellis (NASDAQ: APLS) to ‘overweight’ and raised its price target on APLS to US$64. The upgrade led to the company’s stock price rising by 4.3% on September 15, 2023.
Broker BMO upgraded its rating on FSLR as it sees an attractive entry point in the stock after its recent weakness. FSLR had a mean recommendation rating of 2.2 and a consensus mean price target of US$246.01 as on September 14, 2023.
TD Cowen raised its price target on off-price retail companies TJX and Ross Stores. TD Cowen raised its price target on TJX to US$99 and on ROST to US$137 on September 12, 2023.
BofA raised its rating on pharmaceutical firm Gilead to ‘buy’ on September 8, 2023. The upgrade led the company’s stock price to rise by 3.3% on September 8, 2023.